<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144052</url>
  </required_header>
  <id_info>
    <org_study_id>EOC.NC.09.01</org_study_id>
    <nct_id>NCT01144052</nct_id>
  </id_info>
  <brief_title>Natalizumab De-escalation With Interferon Beta-1b</brief_title>
  <official_title>De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Claudio Gobbi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Civico, Lugano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Civico, Lugano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young
      adults. The management of MS-patients requires treatment with disease-modifying agents,
      monoclonal antibodies such as natalizumab or immunosuppressants. Natalizumab showed good
      efficacy and is approved for treatment of relapsing MS with a number of restrictions due to
      safety issues. Cognitive data related to natalizumab treatment are still scarce.
      Interferon-beta-1b is approved for high-frequency, subcutaneous (sc) administration in the
      treatment of multiple sclerosis. It reduces the relapse rate, severity, hospitalisation and
      the disease activity as seen on MRI.

      This is a pilot study to explore the concept of de-escalating natalizumab treatment to
      interferon-beta-1b e.o.d compared to continuous treatment with natalizumab in patients with
      relapsing-remitting multiple sclerosis previously treated with natalizumab for 12 months. The
      study is designed as prospective, controlled, randomized, rater-blinded, parallel-group, two
      arm, mono-centric including patients of the Ticino Cohort. One arm will be treated with
      Interferon-beta 1b 250mcg given subcutaneously every other day, the other with Natalizumab
      300 mg given intravenously (i.v.), every four weeks. The treatment duration is 12 months, the
      follow-up period 12 months. The time to first on-study relapse will be compared between the
      to treatment arms (primary outcome). Other efficacy parameter include clinical and
      radiological parameters, patient reported outcome on quality of life and fatigue. Safety is
      assessed by reports of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, there is no cure for multiple sclerosis and the management of MS-patients
      requires treatment with disease-modifying agents such as interferon-beta or glatiramer
      acetate, monoclonal antibodies such as natalizumab or immunsuppressants such as mitoxantrone,
      azathioprine or methotrexate. Acute relapses are usually treated with corticosteroids.
      Natalizumab is a humanized monoclonal antibody directed against α4-integrin, a component of
      VLA-4 (very late antigen-4) present on leukocytes. Following submission of additional safety
      data, the agencies such as Swissmedic or EMEA have issued approval of natalizumab for
      treatment of relapsing MS with a number of restrictions. The preparation has been available
      in Switzerland since 2006. According to the current scientific information, natalizumab
      (Tysabri®) is indicated as a &quot;disease-modifying monotherapy of highly active relapsing MS&quot;
      for the following patient groups: 1) patients showing high levels of disease activity despite
      treatment with an IFN-β preparation, or 2) untreated/treatment-naive patients with rapidly
      progressing relapsing-remitting MS (at least two serious relapses per year).

      The primary objective of this pilot study is to generate first data and hypotheses on the
      concept of de-escalating natalizumab-treated relapsing-remitting multiple sclerosis patients
      to interferon-beta-1b e.o.d compared to continuous treatment on natalizumab for planning of
      further clinical studies regarding safety and efficacy.

      As secondary objectives, clinical, neuropsychological parameters, MRI and laboratory
      parameter and safety aspects will be assessed in accordance to the protocol available for the
      management of patient on natalizumab at our service.

      This is a prospective, controlled, randomized, rater-blinded, parallel-group, monocentric,
      two arm, phase IV pilot study. Patients with relapsing-remitting forms of MS, respecting all
      inclusion/exclusion criteria, will be randomized into two equal-size parallel arms for
      de-escalation to interferon beta-1b (after a month wash-out) or for continued treatment on
      natalizumab.

      it is planned to enrol 20 patients (1/2 in the natalizumab group, 1/2 in the interferon
      beta-1b group. Patients providing written informed consent will be treated for 12 months;
      pre-planned follow-up of further 12 month
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Days Until First On-study Relapse</measure>
    <time_frame>12 months</time_frame>
    <description>Patients were followed-up during 12 months and time to first on-study relapse from randomization was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Relapses</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Relapse Free Patients</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Relapses</measure>
    <time_frame>12 months vs baseline</time_frame>
    <description>Change of Expanded Disability Status Scale (EDSS 1-10). Higher values represent a worser outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Number of new T2-hyperintense lesions, Number of Gd-enhancing lesions on T1-weighted images. Assessments at month 3, 6, 9, 12, 18, 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Recording and reporting according to regulations. Monthly assessments or if necessary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infections</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Natalizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon-beta-1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon beta-1b</intervention_name>
    <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])</description>
    <arm_group_label>Interferon-beta-1b</arm_group_label>
    <other_name>Betaferon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natalizumab</intervention_name>
    <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
    <arm_group_label>Natalizumab</arm_group_label>
    <other_name>Tysabri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male patients with relapsing-remitting forms of multiple sclerosis
             (according to McDonald's criteria)

          -  Age between 18 and 60 years

          -  Natalizumab-treatment for at least 12 month following the current Swiss guidelines for
             treatment initiation

          -  Eligible patients are clinically stable (free from relapses and 6-month confirmed
             disability progression for at least 6 months) while on natalizumab-treatment

          -  Women of potential childbearing with active contraceptive methods

          -  Patients who are willing to undergo study procedures

          -  Patients who are willing and able to sign informed consent

        Exclusion Criteria:

          -  Patients who have previously entered this study

          -  Natalizumab-treatment for less than 12 month following the current Swiss guidelines
             for treatment initiation

          -  Sign of clinical disease activity within the 6 month

          -  One or more relapses and/or 6-month confirmed disability progression during the 6
             months prior to the study

          -  Any disease other than multiple sclerosis that would better explain the patient's
             signs and symptoms

          -  Secondary progressive MS

          -  Primary progressive MS

          -  Pregnancy - Urine pregnancy test at baseline visit - or breast feeding

          -  Uncontrolled, clinically significant heart diseases, such as arrhythmias, angina, or
             uncompensated congestive heart failure

          -  History of severe depression or attempted suicide or current suicidal ideation

          -  Medical or psychiatric conditions that compromise the ability to give informed
             consent, to comply with the protocol, or to complete the study

          -  Uncontrolled seizure disorder

          -  Myopathy or clinically significant liver disease

          -  Inability, in the opinion of the principal investigator or staff, to comply with
             protocol requirements for the duration of the study

          -  Known hypersensitivity to interferon-beta or other human proteins including albumin

          -  Any contraindication for MRI or contrast administration

          -  A history of drug abuse in the 6 months prior to screening

          -  Treatment with any of the following in the 30 days before day 1: systemic
             corticosteroids, ACTH, or other investigational drugs.

          -  Participation in any other study involving investigational or marketed products,
             concomitantly or within 30 days prior to entry in the study

          -  Current participation on other clinical trials

          -  Treatment with drugs which might interfere with the evaluation of study drugs during
             the study protocol

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Gobbi, Dr med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurocenter of Southern Switzerland, Ospedale Civico Lugano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurocenter of Southern Switzerland, Ospedale Civico Lugano</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.eoc.ch</url>
    <description>Homepage of the hospital organisation in Ticino</description>
  </link>
  <link>
    <url>http://www.multiplesklerose.ch</url>
    <description>Homepage of the Swiss Society of Multiple Sclerosis</description>
  </link>
  <reference>
    <citation>Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008 Oct;255(10):1449-63. doi: 10.1007/s00415-008-0061-1. Epub 2008 Oct 29.</citation>
    <PMID>19005625</PMID>
  </reference>
  <reference>
    <citation>Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911-23.</citation>
    <PMID>16510745</PMID>
  </reference>
  <reference>
    <citation>Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910.</citation>
    <PMID>16510744</PMID>
  </reference>
  <reference>
    <citation>IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology. 2001 Dec;57(12 Suppl 5):S3-9.</citation>
    <PMID>11902592</PMID>
  </reference>
  <reference>
    <citation>Paty DW, Li DK; UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology. 2001 Dec;57(12 Suppl 5):S10-5.</citation>
    <PMID>11902589</PMID>
  </reference>
  <reference>
    <citation>Putzki N, Yaldizli O, Tettenborn B, Diener HC. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci. 2009 Oct 15;285(1-2):109-13. doi: 10.1016/j.jns.2009.06.004. Epub 2009 Jun 26.</citation>
    <PMID>19560168</PMID>
  </reference>
  <reference>
    <citation>Ransohoff RM. Natalizumab and PML. Nat Neurosci. 2005 Oct;8(10):1275.</citation>
    <PMID>16189528</PMID>
  </reference>
  <reference>
    <citation>Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993 Feb;20(1):17-29. Review.</citation>
    <PMID>8467424</PMID>
  </reference>
  <results_reference>
    <citation>Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013 Aug 2;13:101. doi: 10.1186/1471-2377-13-101.</citation>
    <PMID>23915113</PMID>
  </results_reference>
  <results_reference>
    <citation>Zecca C, Riccitelli GC, Calabrese P, Pravatà E, Candrian U, Guttmann CR, Gobbi C. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol. 2014 Feb 28;14:38. doi: 10.1186/1471-2377-14-38.</citation>
    <PMID>24576156</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <results_first_submitted>October 31, 2013</results_first_submitted>
  <results_first_submitted_qc>March 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2014</results_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Civico, Lugano</investigator_affiliation>
    <investigator_full_name>Claudio Gobbi</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Natalizumab</keyword>
  <keyword>Interferon-beta 1b</keyword>
  <keyword>De-escalation</keyword>
  <keyword>Ticino</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Natalizumab</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 2010 to 2011 Out-patients of Neurology ambulatory</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Natalizumab</title>
          <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.</description>
        </group>
        <group group_id="P2">
          <title>Interferon-beta-1b</title>
          <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Natalizumab</title>
          <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.</description>
        </group>
        <group group_id="B2">
          <title>Interferon-beta-1b</title>
          <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="10.83"/>
                    <measurement group_id="B2" value="39" spread="13.26"/>
                    <measurement group_id="B3" value="41" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Until First On-study Relapse</title>
        <description>Patients were followed-up during 12 months and time to first on-study relapse from randomization was recorded.</description>
        <time_frame>12 months</time_frame>
        <population>All enrolled and randomized patients fulfilled the criteria for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Until First On-study Relapse</title>
          <description>Patients were followed-up during 12 months and time to first on-study relapse from randomization was recorded.</description>
          <population>All enrolled and randomized patients fulfilled the criteria for analysis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">This value is not available, because zero patients experienced a relapse.</measurement>
                    <measurement group_id="O2" value="103" lower_limit="103" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No statistical hypothesis tests for efficacy were performed as this was a pilot study serving to generate first data and hypotheses.</non_inferiority_desc>
            <p_value>0.125</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Relapses</title>
        <time_frame>12 months</time_frame>
        <population>All enrolled and randomized patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapses</title>
          <population>All enrolled and randomized patients were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <method>non-parametric</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Relapses</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Relapses</title>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <method>non-parametric</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Relapse Free Patients</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.
Natalizumab: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day
interferon beta-1b: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Relapse Free Patients</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Relapses</title>
        <description>Change of Expanded Disability Status Scale (EDSS 1-10). Higher values represent a worser outcome.</description>
        <time_frame>12 months vs baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.
Natalizumab: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day
interferon beta-1b: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Relapses</title>
          <description>Change of Expanded Disability Status Scale (EDSS 1-10). Higher values represent a worser outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRI Parameters</title>
        <description>Number of new T2-hyperintense lesions, Number of Gd-enhancing lesions on T1-weighted images. Assessments at month 3, 6, 9, 12, 18, 24.</description>
        <time_frame>12 months</time_frame>
        <population>All enrolled and randomized patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>MRI Parameters</title>
          <description>Number of new T2-hyperintense lesions, Number of Gd-enhancing lesions on T1-weighted images. Assessments at month 3, 6, 9, 12, 18, 24.</description>
          <population>All enrolled and randomized patients were analyzed.</population>
          <units>Lesions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>nT2L month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nT2L month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nT2L month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nT2L month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GD+L month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GD+L month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GD+L month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GD+L month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>No statistical hypothesis tests for efficacy were performed, as this was pilot study serving to generate first data and hypotheses.</non_inferiority_desc>
            <p_value>0.234</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>p-value refers to nT2L at month 12</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Recording and reporting according to regulations. Monthly assessments or if necessary.</description>
        <time_frame>12 months</time_frame>
        <population>All patients enrolled and randomized were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Recording and reporting according to regulations. Monthly assessments or if necessary.</description>
          <population>All patients enrolled and randomized were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with injections site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infections</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Natalizumab</title>
            <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.</description>
          </group>
          <group group_id="O2">
            <title>Interferon-beta-1b</title>
            <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infections</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 12 months of the trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Natalizumab</title>
          <description>Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers’ instructions.</description>
        </group>
        <group group_id="E2">
          <title>Interferon-beta-1b</title>
          <description>250 mcg (8 MIU) subcutaneous injections every other day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <description>One patient in the NTZ arm experienced a gastroenteritis requiring his hospitalisation. The patient recovered without sequelae and continued the study. The adverse event was judged to be unrelated to the study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Claudio Globbi, Dr. med.</name_or_title>
      <organization>Ospedale Civico</organization>
      <phone>+41 91 811 6921</phone>
      <email>claudio.gobbi@eoc.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

